Sunpharma Ltd — Q2 FY25
Sun Pharma delivered a strong Q2 FY25 with consolidated sales of INR 13,264 crore, up 10.5% YoY, driven by US specialty growth (+20.3% to $517M) and India formulation growth (+1...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q1 FY25
R&D spend to step up to 8-10% of sales for FY25
Management expects R&D investment to increase in subsequent quarters, with full-year guidance of 8-10% of sales.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q1 FY25
Leqselvi launch pending court decision on preliminary injunction
Launch timing of Leqselvi will be governed by court ruling on Incyte's motion; company opposes and seeks early outcome.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1